17 Feb 2022 , 01:34 AM
Alkem Laboratories has signed a license agreement with Harvard Universitys Office of Technology Development OTD enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy foot ulcers peripheral arterial disease PAD and other injuries caused by vascular disease The license grants Alkem commercialization rights in the United States and India
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.